MX2019007615A - Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1. - Google Patents

Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1.

Info

Publication number
MX2019007615A
MX2019007615A MX2019007615A MX2019007615A MX2019007615A MX 2019007615 A MX2019007615 A MX 2019007615A MX 2019007615 A MX2019007615 A MX 2019007615A MX 2019007615 A MX2019007615 A MX 2019007615A MX 2019007615 A MX2019007615 A MX 2019007615A
Authority
MX
Mexico
Prior art keywords
tumor
expression
immune cell
cell imaging
imaging based
Prior art date
Application number
MX2019007615A
Other languages
English (en)
Inventor
G Pomper Martin
Nimmagadda Sridhar
Chatterjee Samit
G Lesniak Wojciech
Kumar Dhiraj
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2019007615A publication Critical patent/MX2019007615A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La materia actualmente descrita proporciona composiciones, equipos, y métodos que comprenden agentes trazadores que pueden detectar el Ligado 1 de Muerte Programada (PD-L1). Los agentes trazadores actualmente descritos se pueden usar para detectar enfermedades y trastornos, tal como cáncer, infección, e inflamación, en un sujeto.
MX2019007615A 2016-12-23 2017-12-21 Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1. MX2019007615A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438575P 2016-12-23 2016-12-23
US201762519534P 2017-06-14 2017-06-14
PCT/US2017/068025 WO2018119313A1 (en) 2016-12-23 2017-12-21 Tumor and immune cell imaging based on pd-l1 expression

Publications (1)

Publication Number Publication Date
MX2019007615A true MX2019007615A (es) 2019-11-05

Family

ID=62627749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007615A MX2019007615A (es) 2016-12-23 2017-12-21 Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1.

Country Status (11)

Country Link
US (1) US11607466B2 (es)
EP (1) EP3558395A4 (es)
JP (2) JP2020514278A (es)
KR (2) KR102662725B1 (es)
CN (1) CN110366432A (es)
AU (1) AU2017382282A1 (es)
BR (1) BR112019012986A2 (es)
CA (1) CA3048229A1 (es)
IL (1) IL267572A (es)
MX (1) MX2019007615A (es)
WO (1) WO2018119313A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109512798B (zh) * 2019-01-15 2022-05-13 南京从一医药科技有限公司 一种用于抗肿瘤免疫治疗的药物组合物纳米体系
CN111662270A (zh) * 2019-03-05 2020-09-15 中国医学科学院药物研究所 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途
CN110898234B (zh) * 2019-12-25 2020-12-22 河南大学 一种二维铋纳米复合材料及其制备方法和应用
TWI833056B (zh) 2019-12-31 2024-02-21 財團法人工業技術研究院 核酸藥物複合體以及其用途
CN112067586B (zh) * 2020-06-24 2021-08-03 江南大学 一种基于荧光淬灭拉曼增强的***特异性抗原双信号光谱分析方法
CA3188677A1 (en) * 2020-08-07 2022-02-10 Sridhar Nimmagadda Imaging and targeting programmed death ligand-1 (pd-li) expression
DE102020130954A1 (de) 2020-11-23 2022-05-25 Universität Duisburg-Essen Markierungspartikel für Raman-Streuung und/oder Fluoreszenz-Strahlung
CN114853851B (zh) * 2021-02-04 2023-08-15 南方医科大学南方医院 靶向pd-l1多肽探针及其在制备pet显像剂中的应用
CN113341023B (zh) * 2021-06-30 2022-12-23 大连医科大学附属第一医院 一种基于液质联用的血清二氨基庚二酸的检测试剂盒及检测方法与应用
WO2023014999A1 (en) * 2021-08-06 2023-02-09 The Johns Hopkins University Aluminum fluoride radiosynthesis of [18f]dk222
CN115364247A (zh) * 2021-09-15 2022-11-22 中国人民解放军海军军医大学第一附属医院 一种靶向显影剂、制备方法及其应用
CN114010655B (zh) * 2021-11-02 2023-02-03 安徽医科大学第一附属医院 一种识别和降解***癌细胞表面的pd-l1的金纳米星及其制备方法和应用
CN114569745A (zh) * 2022-03-18 2022-06-03 哈尔滨医科大学 一种靶向pd-l1的多肽pet分子成像探针及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004016968D1 (de) * 2003-03-19 2008-11-20 Universitaetsspital Basel Auf substanz p basierende radiomarkierte konjugate und deren gebrauch
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
US9649394B2 (en) * 2010-11-22 2017-05-16 The General Hospital Corporation Compositions and methods for in vivo imaging
US20140316255A1 (en) 2011-09-02 2014-10-23 Ellis Garai Raman Imaging Devices and Methods of Molecular Imaging
US11268958B2 (en) * 2012-09-14 2022-03-08 The Johns Hopkins University Bacteria-specific labeled substrtates as imaging biomarkers to diagnose, locate, and monitor infections
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MX2017003201A (es) * 2014-09-11 2017-05-23 Bristol Myers Squibb Co Inhibidores macrociclicos de las interacciones proteina/proteina de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1.
ES2822990T3 (es) * 2014-11-25 2021-05-05 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
EA038019B1 (ru) * 2016-05-19 2021-06-23 Бристол-Маерс Сквибб Компани Иммуномодуляторы для пэт-визуализации

Also Published As

Publication number Publication date
KR102662725B1 (ko) 2024-04-30
US20190314531A1 (en) 2019-10-17
JP2020514278A (ja) 2020-05-21
KR20190102018A (ko) 2019-09-02
CA3048229A1 (en) 2018-06-28
CN110366432A (zh) 2019-10-22
BR112019012986A2 (pt) 2019-12-03
EP3558395A1 (en) 2019-10-30
AU2017382282A1 (en) 2019-07-11
KR20240023665A (ko) 2024-02-22
WO2018119313A1 (en) 2018-06-28
US11607466B2 (en) 2023-03-21
IL267572A (en) 2019-08-29
EP3558395A4 (en) 2020-08-12
JP2023052071A (ja) 2023-04-11

Similar Documents

Publication Publication Date Title
MX2019007615A (es) Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1.
PH12017500803A1 (en) Anti-pd-1 antibodies
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2019007276A (es) Composiciones y métodos para mejora o aumento de la producción de ifn tipo i.
SG11201900171QA (en) Antibody for anti-claudin 18a2 and use thereof
MY199019A (en) Pd-1 antibodies
MY191035A (en) Affinity-oligonucleotide conjugates and uses thereof
MX2018004546A (es) Composiciones y métodos para la inhibicion de antígenos específicos de linaje.
MY196173A (en) Cot Modulators And Methods Of Use Thereof
MY193404A (en) Anti-pd-1 antibodies and methods of use thereof
TR201819571T4 (tr) Hem immün hücrelerde hem de patolojik hücrelerde bulunan antijenleri hedef almak amacıyla değiştirilmiş immünoterapiye yönelik hücreler.
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2014009219A (es) Compuestos de purinona como inhibidores de quinasas.
WO2015067570A3 (en) Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
MX2015012922A (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2017015127A (es) Particulas modificadas por carbohidratos y formulaciones en particulas para modular una respuesta inmunitaria.